KR102059736B1 - 융합 단백질 - Google Patents

융합 단백질 Download PDF

Info

Publication number
KR102059736B1
KR102059736B1 KR1020177031825A KR20177031825A KR102059736B1 KR 102059736 B1 KR102059736 B1 KR 102059736B1 KR 1020177031825 A KR1020177031825 A KR 1020177031825A KR 20177031825 A KR20177031825 A KR 20177031825A KR 102059736 B1 KR102059736 B1 KR 102059736B1
Authority
KR
South Korea
Prior art keywords
val
insulin
ser
glu
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177031825A
Other languages
English (en)
Korean (ko)
Other versions
KR20170134614A (ko
Inventor
데이비드 브루스 발드윈
존 마이클 빌스
조나단 웨슬리 데이
크렉 듀언 디킨슨
앤드류 이홀 코릿코
그레고리 알란 라자르
Original Assignee
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55953435&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102059736(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 일라이 릴리 앤드 캄파니 filed Critical 일라이 릴리 앤드 캄파니
Publication of KR20170134614A publication Critical patent/KR20170134614A/ko
Application granted granted Critical
Publication of KR102059736B1 publication Critical patent/KR102059736B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
KR1020177031825A 2015-05-07 2016-04-28 융합 단백질 Active KR102059736B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562158079P 2015-05-07 2015-05-07
US62/158,079 2015-05-07
PCT/US2016/029807 WO2016178905A1 (en) 2015-05-07 2016-04-28 Fusion proteins

Publications (2)

Publication Number Publication Date
KR20170134614A KR20170134614A (ko) 2017-12-06
KR102059736B1 true KR102059736B1 (ko) 2019-12-26

Family

ID=55953435

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177031825A Active KR102059736B1 (ko) 2015-05-07 2016-04-28 융합 단백질

Country Status (40)

Country Link
US (5) US9855318B2 (https=)
EP (1) EP3292141B1 (https=)
JP (1) JP6591562B2 (https=)
KR (1) KR102059736B1 (https=)
CN (1) CN107531806B (https=)
AR (1) AR105616A1 (https=)
AU (1) AU2016257659B2 (https=)
CA (1) CA2981102A1 (https=)
CL (1) CL2017002761A1 (https=)
CO (1) CO2017011301A2 (https=)
CR (1) CR20170469A (https=)
CY (1) CY1122929T1 (https=)
DK (1) DK3292141T3 (https=)
DO (1) DOP2017000258A (https=)
EA (1) EA039770B1 (https=)
EC (1) ECSP17073650A (https=)
ES (1) ES2799099T3 (https=)
HR (1) HRP20200503T1 (https=)
IL (1) IL254965B (https=)
JO (1) JO3658B1 (https=)
LT (1) LT3292141T (https=)
MA (1) MA42037B1 (https=)
MD (1) MD3292141T2 (https=)
ME (1) ME03709B (https=)
MX (1) MX388594B (https=)
MY (1) MY183025A (https=)
NZ (1) NZ736470A (https=)
PE (1) PE20180507A1 (https=)
PH (1) PH12017502025B1 (https=)
PL (1) PL3292141T3 (https=)
PT (1) PT3292141T (https=)
RS (1) RS60044B1 (https=)
SG (1) SG11201708194WA (https=)
SI (1) SI3292141T1 (https=)
SV (1) SV2017005548A (https=)
TN (1) TN2018000059A1 (https=)
TW (1) TWI656132B (https=)
UA (1) UA122146C2 (https=)
WO (1) WO2016178905A1 (https=)
ZA (1) ZA201706334B (https=)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2784603T3 (es) 2015-06-02 2020-09-29 Novo Nordisk As Insulinas con extensiones recombinantes polares
EP3355931B1 (en) 2015-10-01 2024-06-26 Novo Nordisk A/S Protein conjugates
CN113147180A (zh) 2016-07-27 2021-07-23 惠普发展公司，有限责任合伙企业 用于具有数字流体液位传感器的流体供应墨盒的水平接口
WO2018107117A1 (en) 2016-12-09 2018-06-14 Akston Biosciences Corporation Insulin-fc fusions and methods of use
TR201703622A1 (tr) * 2017-03-09 2018-09-21 Univ Yeditepe Obezi̇te tedavi̇si̇ i̇çi̇n bi̇r ürün
JP2020513019A (ja) * 2017-04-05 2020-04-30 ノヴォ ノルディスク アー／エス オリゴマー伸長インスリン−Ｆｃコンジュゲート
CN112020365A (zh) * 2018-01-26 2020-12-01 豪夫迈·罗氏有限公司 组合物和使用方法
KR20210025522A (ko) 2018-06-25 2021-03-09 유니버시티 오브 워싱톤 강력하고 선택적인 인터루킨 모방체의 드 노보 디자인
US11267862B2 (en) 2018-06-29 2022-03-08 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
KR20210029210A (ko) 2018-06-29 2021-03-15 악스톤 바이오사이언시스 코퍼레이션 초장기 작용 인슐린-fc 융합 단백질 및 사용 방법
WO2020074544A1 (en) 2018-10-10 2020-04-16 Novo Nordisk A/S Oligomer extended insulin-fc conjugates and their medical use
JP2022511390A (ja) 2018-11-20 2022-01-31 ユニバーシティ オブ ワシントン 分割インターロイキン模倣体およびその使用
WO2020190591A1 (en) * 2019-03-15 2020-09-24 Eli Lilly And Company Preserved formulations
WO2021011827A1 (en) * 2019-07-16 2021-01-21 Akston Biosciences Corporation Ultra-long acting insulin-fc fusion proteins and methods of use
TWI844709B (zh) 2019-07-31 2024-06-11 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
CN114555792A (zh) 2019-10-15 2022-05-27 伊莱利利公司 重组改造的、脂肪酶/酯酶缺陷型哺乳动物细胞系
KR20250142943A (ko) * 2019-12-19 2025-09-30 악스톤 바이오사이언시스 코퍼레이션 초-장기 작용 인슐린-fc 융합 단백질 및 사용 방법
US11186623B2 (en) 2019-12-24 2021-11-30 Akston Bioscience Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
US20230340071A1 (en) 2020-03-16 2023-10-26 Neoleukin Therapeutics, Inc. Interleukin-2 Receptor Beta (IL-2RB) Binding Polypeptides
CN115515972A (zh) 2020-04-07 2022-12-23 尼尔路金治疗公司 血管紧张素转换酶2(ace2)的从头蛋白诱饵
US11192930B2 (en) 2020-04-10 2021-12-07 Askton Bioscences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
LT3972987T (lt) 2020-04-10 2023-09-25 Akston Biosciences Corporation Antigenui specifinė imunoterapija, skirta sulietiems covid-19 baltymams ir naudojimo būdai
US11198719B2 (en) 2020-04-29 2021-12-14 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
CN113968911B (zh) * 2020-07-24 2023-10-10 江苏晟斯生物制药有限公司 胰岛素-Fc融合蛋白及其应用
WO2022096704A1 (en) * 2020-11-06 2022-05-12 Amgen Inc. Antigen binding domain with reduced clipping rate
TW202237174A (zh) * 2020-12-14 2022-10-01 美商美國禮來大藥廠 治療糖尿病之方法
EP4373861A4 (en) 2021-07-23 2025-08-20 Akston Biosciences Corp INSULIN-FC FUSION PROTEINS AND METHODS OF USE FOR TREATING CANCER
WO2023044318A2 (en) 2021-09-15 2023-03-23 Neoleukin Therapeutics, Inc. Interleukin-2 receptor βeta (il-2rβ) binding polypeptides
TWI871539B (zh) * 2021-11-15 2025-02-01 美商美國禮來大藥廠 可保存之調配物
KR20240158331A (ko) * 2022-03-16 2024-11-04 베이징 투오 지에 바이오파마수티컬 컴퍼니 리미티드 인간 인슐린 유사체, 이의 융합 단백질 및 의약적 용도
IL317049A (en) 2022-05-18 2025-01-01 Protomer Tech Inc Aromatic boron-containing compounds and related insulin analogs
JP2025522529A (ja) 2022-06-23 2025-07-15 サノフイ 一本鎖インスリン及びそのＦｃ結合体
WO2024137820A1 (en) * 2022-12-20 2024-06-27 The Board Of Trustees Of The Leland Stanford Junior University Insulin receptor antagonist
CN115894720B (zh) * 2023-01-16 2024-07-09 中国科学院上海药物研究所 一种长效胰岛素-Fc融合蛋白
AU2024265269A1 (en) 2023-05-03 2025-11-06 Eli Lilly And Company Methods and systems for managing diabetes
WO2025059010A1 (en) 2023-09-11 2025-03-20 Eli Lilly And Company Methods and systems for managing diabetes
CN121752601A (zh) * 2023-09-20 2026-03-27 上海迈晋生物医药科技有限公司 一种人胰岛素类似物融合蛋白的药物组合物及其医药用途
WO2025080923A1 (en) 2023-10-13 2025-04-17 Eli Lilly And Company Insulin-fc fusion proteins
US12454565B2 (en) 2024-03-21 2025-10-28 Akston Biosciences Corporation PD-L1 analog fusion proteins for antigen specific immunotherapy and methods of use

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007536902A (ja) * 2003-06-12 2007-12-20 イーライ リリー アンド カンパニー Ｇｌｐ−１アナログ複合タンパク質
JP2010531134A (ja) * 2007-05-30 2010-09-24 ポステク アカデミー−インダストリー ファウンデイション 免疫グロブリン融合タンパク質
CN103509118A (zh) * 2012-06-15 2014-01-15 郭怀祖 胰岛素-Fc融合蛋白
WO2014152955A1 (en) * 2013-03-14 2014-09-25 Regeneron Pharmaceuticals, Inc. Apelin fusion proteins and uses thereof

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US5514646A (en) 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
HU225496B1 (en) 1993-04-07 2007-01-29 Scios Inc Pharmaceutical compositions of prolonged delivery, containing peptides
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
EP0741188A3 (en) 1995-05-05 1999-07-14 Eli Lilly And Company Single chain insulin with high bioactivity
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
WO2001000223A2 (en) 1999-06-25 2001-01-04 Minimed Inc. Multiple agent diabetes therapy
KR100449454B1 (ko) 2000-10-02 2004-09-21 이현철 단일사슬 인슐린 유도체의 유전자를 포함하는 당뇨병치료용 벡터
IL155812A0 (en) 2000-12-07 2003-12-23 Lilly Co Eli Glp-1 fusion proteins
CZ2004710A3 (cs) 2001-12-20 2005-02-16 Eli Lilly And Company Inzulínová sloučenina s protrahovaným účinkem
US7448763B2 (en) 2003-10-02 2008-11-11 Carl Zeiss Smt Ag Optical subassembly and projection objective in semiconductor lithography
EP1692168B1 (en) 2003-12-03 2011-07-20 Novo Nordisk A/S Single-chain insulin
JP2008533100A (ja) 2005-03-18 2008-08-21 ノボ ノルディスク アクティーゼルスカブ Ｐｅｇ化された単鎖インスリン
US20090069216A1 (en) 2006-02-21 2009-03-12 Novo Nordisk A/S Single-Chain Insulin Analogues and Pharmaceutical Formulations Thereof
WO2007104737A1 (en) 2006-03-13 2007-09-20 Novo Nordisk A/S Acylated single chain insulin
JP2009530243A (ja) 2006-03-13 2009-08-27 ノボ・ノルデイスク・エー／エス アシル化単鎖インスリン
RU2524150C2 (ru) 2006-09-22 2014-07-27 Ново Нордиск А/С Аналоги инсулина, устойчивые к протеазам
WO2008043033A2 (en) 2006-10-04 2008-04-10 Case Western Reserve University Fibrillation-resistant insulin and insulin analogues
WO2008049711A1 (en) 2006-10-27 2008-05-02 Novo Nordisk A/S Peptide extended insulins
ATE499088T1 (de) 2007-07-10 2011-03-15 Lilly Co Eli Glp-1-fc fusionsprotein-formulierung
WO2009112583A2 (en) 2008-03-14 2009-09-17 Novo Nordisk A/S Protease-stabilized insulin analogues
HUE032284T2 (en) * 2008-03-18 2017-09-28 Novo Nordisk As Protease-stabilized, acylated insulin analogues
EP2296692A4 (en) 2008-04-22 2012-06-06 Univ Case Western Reserve ISOFORM-SPECIFIC INSULIN ANALOG
GB0812019D0 (en) 2008-07-02 2008-08-06 Asterion Ltd Insulin
MX2011000861A (es) 2008-07-23 2011-06-21 Hanmi Holdings Co Ltd Un complejo polipeptidico que consiste en un polimero no-peptidil que posee tres terminaciones funcionales.
AR081066A1 (es) 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
KR101324828B1 (ko) 2010-06-08 2013-11-01 한미사이언스 주식회사 면역글로불린 단편을 이용한 단쇄 인슐린 아날로그 약물 결합체
JP5969469B2 (ja) 2010-06-16 2016-08-17 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ インスリン受容体に対して高い活性を示す単鎖インスリンアゴニスト
JP6125436B2 (ja) 2011-02-09 2017-05-10 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ 凍結乾燥製剤
CN102718870B (zh) * 2011-05-24 2014-04-30 马鞍山中美德康生物科技有限公司 一种胰岛素生物增敏剂及其应用
UA113626C2 (xx) 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
CN102516393B (zh) * 2011-11-30 2017-03-15 北京康明百奥新药研发有限公司 胰岛素模拟肽融合蛋白和突变体及其应用
US20150111820A1 (en) 2012-07-09 2015-04-23 Novo Nordisk A/S Novel use of insulin derivatives
AR091902A1 (es) 2012-07-25 2015-03-11 Hanmi Pharm Ind Co Ltd Formulacion liquida de un conjugado de insulina de accion prolongada
AR092862A1 (es) 2012-07-25 2015-05-06 Hanmi Pharm Ind Co Ltd Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
EP3395358B1 (en) 2012-09-26 2019-11-06 Indiana University Research and Technology Corporation Insulin analog dimers
AU2013337250B2 (en) 2012-11-05 2017-06-22 Case Western Reserve University Long-acting single-chain insulin analogues
MX361083B (es) 2013-02-26 2018-11-27 Hanmi Pharma Co Ltd Conjugado de insulina específico de sitio.
JP6499184B2 (ja) 2013-10-07 2019-04-10 ノヴォ ノルディスク アー／エス インスリン類似体の新規な誘導体
CR20160376A (es) 2014-01-20 2016-10-07 Hanmi Pharm Ind Co Ltd Insulina de acción prolongada y uso de la misma
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
AR100695A1 (es) 2014-05-30 2016-10-26 Hanmi Pharm Ind Co Ltd Composición para el tratamiento de diabetes mellitus que comprende insulina y un agonista dual glp-1 / glucagón
KR20160001391A (ko) 2014-06-27 2016-01-06 한미약품 주식회사 신규한 지속형 인슐린 아날로그 결합체 및 이의 용도
KR20160007295A (ko) 2014-07-11 2016-01-20 한미약품 주식회사 인슐린 아날로그
BR112017004544A2 (pt) 2014-10-06 2018-01-23 Univ Case Western Reserve insulina de cadeia simples, composição farmacêutica e método para tratar diabetes mellitus
TN2017000178A1 (en) 2014-11-21 2018-10-19 Merck Sharp & Dohme Insulin receptor partial agonists
EP3260139A4 (en) 2015-02-17 2018-09-05 Hanmi Pharm. Co., Ltd. Long-acting insulin or insulin analogue complex
CN110134210A (zh) 2019-04-16 2019-08-16 深圳市国鑫恒宇科技有限公司 一种服务器一体机的温度控制方法、系统、装置及存储介质

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007536902A (ja) * 2003-06-12 2007-12-20 イーライ リリー アンド カンパニー Ｇｌｐ−１アナログ複合タンパク質
JP2010531134A (ja) * 2007-05-30 2010-09-24 ポステク アカデミー−インダストリー ファウンデイション 免疫グロブリン融合タンパク質
CN103509118A (zh) * 2012-06-15 2014-01-15 郭怀祖 胰岛素-Fc融合蛋白
WO2014152955A1 (en) * 2013-03-14 2014-09-25 Regeneron Pharmaceuticals, Inc. Apelin fusion proteins and uses thereof

Also Published As

Publication number Publication date
MX2017014284A (es) 2018-03-23
US9855318B2 (en) 2018-01-02
SI3292141T1 (sl) 2020-04-30
PH12017502025A1 (en) 2018-04-02
US12059452B2 (en) 2024-08-13
CN107531806A (zh) 2018-01-02
DK3292141T3 (da) 2020-04-20
EA201792199A1 (ru) 2018-03-30
ME03709B (me) 2021-01-20
AR105616A1 (es) 2017-10-25
CR20170469A (es) 2017-11-14
US20220211818A1 (en) 2022-07-07
ECSP17073650A (es) 2018-02-28
US11253574B2 (en) 2022-02-22
SV2017005548A (es) 2018-04-24
CO2017011301A2 (es) 2018-03-20
EP3292141A1 (en) 2018-03-14
JP6591562B2 (ja) 2019-10-16
KR20170134614A (ko) 2017-12-06
UA122146C2 (uk) 2020-09-25
EA039770B1 (ru) 2022-03-11
WO2016178905A1 (en) 2016-11-10
MA42037B1 (fr) 2020-03-31
HK1244019A1 (en) 2018-07-27
TW201712029A (zh) 2017-04-01
CL2017002761A1 (es) 2018-05-18
PE20180507A1 (es) 2018-03-09
CA2981102A1 (en) 2016-11-10
DOP2017000258A (es) 2017-12-31
PL3292141T3 (pl) 2020-06-29
JO3658B1 (ar) 2020-08-27
AU2016257659A1 (en) 2017-10-12
IL254965B (en) 2021-03-25
JP2018515088A (ja) 2018-06-14
HRP20200503T1 (hr) 2020-06-26
MX388594B (es) 2025-03-20
US10709766B2 (en) 2020-07-14
LT3292141T (lt) 2020-03-25
RS60044B1 (sr) 2020-04-30
PT3292141T (pt) 2020-04-22
AU2016257659B2 (en) 2018-08-09
US20160324932A1 (en) 2016-11-10
PH12017502025B1 (en) 2018-04-02
US20250032588A1 (en) 2025-01-30
CN107531806B (zh) 2022-06-07
IL254965A0 (en) 2017-12-31
SG11201708194WA (en) 2017-11-29
TWI656132B (zh) 2019-04-11
TN2018000059A1 (en) 2019-07-08
ES2799099T3 (es) 2020-12-14
EP3292141B1 (en) 2020-02-12
MY183025A (en) 2021-02-07
ZA201706334B (en) 2020-01-29
US20180177851A1 (en) 2018-06-28
CY1122929T1 (el) 2021-10-29
MD3292141T2 (ro) 2020-07-31
BR112017020502A2 (pt) 2018-07-03
NZ736470A (en) 2019-04-26
US20200390865A1 (en) 2020-12-17

Similar Documents

Publication Publication Date Title
US12059452B2 (en) Fusion proteins
KR102449145B1 (ko) 지속형 인슐린 아날로그 결합체 및 지속형 인슐린 분비 펩타이드 결합체를 포함하는 당뇨병 치료용 조성물
KR101238979B1 (ko) Ｐｅｇ화된 인슐린 리스프로 화합물
JP2015164916A (ja) 新規Ｅｘｅｎｄｉｎ変異体及びその複合物
EP1515749B1 (en) Combined use of a modulator of cd3 and a glp-1 compound
KR20140018798A (ko) 지속형 인슐린분비 펩타이드 결합체 액상 제제
KR20110021758A (ko) 이형체-특이적 인슐린 유사체
US12312390B2 (en) Rapid-acting insulin analogues of enhanced stability
US10745458B2 (en) Non-standard insulin analogues
BR112021005419A2 (pt) conjugado que compreende um ou mais polímeros hidrofílicos, uso do mesmo e composição farmacêutica
JP2025509433A (ja) ヒトインスリン類似体、その融合タンパク質及び医薬的使用
HK1244019B (en) Fusion proteins
BR112017020502B1 (pt) Proteína de fusão e seus usos, homodímero e seus usos, e composição farmacêutica
WO2025080923A1 (en) Insulin-fc fusion proteins
EA052546B1 (ru) Аналог человеческого инсулина, его слитый белок и их медицинское применение

Legal Events

Date Code Title Description
A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20221123

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 7